Drug Profile
KiroVAX 001
Alternative Names: KiroVAX001; TAPA-loaded DC vaccine - KiroVAX-001; TAPA-pulsed DC vaccine - KiroVAX-001; TAPA-pulsed dendritic cell vaccine - KiroVAX-001Latest Information Update: 30 Sep 2020
Price :
$50
*
At a glance
- Originator Kiromic
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 30 Sep 2020 No development reported - Phase-I/II for Haematological malignancies (Combination therapy, Second-line therapy or greater) in USA (SC)
- 14 Oct 2019 Kiromic terminates phase I/II trial in Haematological malignancies (Second-line therapy or greater, Combination therapy) in USA prior to enrolment (SC) (NCT02709993)
- 28 Jul 2017 Phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater, Combination therapy) in USA (SC) (NCT02709993)